Fig. 4: Microbial antitumour vaccine efficacy in orthotopic melanoma.
From: Probiotic neoantigen delivery vectors for precision cancer immunotherapy
a, Melanoma therapeutic design. Left, a Circos plot, mutanome B16F10. Right, an immunoblot with neoantigen constructs. b–e,g–i, C57BL/6 mice with orthotopic B16F10 tumours treated starting 9 days post-engraftment. b, Intratumoural treatment every 3–5 days. Tumour growth curves (n = 7 mice per group, ****P < 0.0001; NS, P > 0.05). c, Intravenous treatment every 3–5 days. Tumour growth curves (****P < 0.0001; NS, P > 0.05). d, Kaplan–Meier survival curves, mice from c (***P = 0.0001, log-rank Mantel–Cox test). e, Intravenous treatment, EcNcΔlon/ΔompT/LLO+ nAg42 (n = 6 mice). Microbial CFU g−1, LOD = 1 × 103 CFU g−1. f, Purified splenic T cells, specific lysis B16F10-Luc (n = 5 mice per group, ***P = 0.001, ****P < 0.0001; NS, P > 0.05). g, Intravenous treatment every 3–5 days. Tumour growth curves (n = 6 mice for OVA, n = 7 for isotype, n = 8 for other groups, **P = 0.0082, ****P < 0.0001; NS, P > 0.05). h,i, Intravenous treatment on days 9 and 12. h, Left, the number of CD103+XCR1+ cDC1 per mg (*P = 0.0103, **P = 0.0030; NS, P > 0.05). Right, the number of CD301b+ cDC2 per mg (**P = 0.0038, **P = 0.0064; NS, P > 0.05). i, Left, the number of Foxp3−CD4+ T cells per mg (**P = 0.0015, ***P = 0.0008; NS, P > 0.05). Right, the number of CD8+ T cells mg−1 (**P = 0.0022, **P = 0.0047; NS, P > 0.05). b,c,g, two-way ANOVA, or f,h,i, one-way ANOVA, with b, Šídák’s or c,f–i, Tukey’s multiple comparisons test. h,i, n = 8 mice for nAg42, n = 7 for other groups. c,d, n = 5 mice for PBS, n = 7 for other groups. b,c,e–i, Data are mean ± s.e.m. Gel source data are in Supplementary Fig. 2.
